What is the expected growth forecast for the Sickle Cell Disease Diagnosis and Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Sickle Cell Disease Diagnosis and Treatment market?

Increasing prevalence and advances in diagnostic technologies drive the market.

What are the major challenges in the Sickle Cell Disease Diagnosis and Treatment market?

High treatment costs and limited access to healthcare hinder market growth.

Which regions are the leaders in the Sickle Cell Disease Diagnosis and Treatment market?

North America and Europe are the leading regions due to high awareness.

Who are the top companies in the Sickle Cell Disease Diagnosis and Treatment market?

Major players include Novartis, Pfizer, and bluebird bio.

What are the future opportunities in the Sickle Cell Disease Diagnosis and Treatment market?

Gene therapy and emerging markets offer significant future outlook opportunities.

How does technology impact the Sickle Cell Disease Diagnosis and Treatment market?

Advances in genetic testing and precision medicine improve diagnosis and treatment.

What is the regulatory landscape like for the Sickle Cell Disease Diagnosis and Treatment market?

Stringent regulations and approval processes influence market growth and development.

What does the future outlook of the Sickle Cell Disease Diagnosis and Treatment market look like?

The market is expected to experience steady growth due to increasing awareness and advances.

Sickle Cell Disease Diagnosis and Treatment Market Metrics & Forecast Analysis 2033

Sickle Cell Disease Diagnosis and Treatment by Application (Child, Adult), by Types (Diagnosis, Treatment), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $13.3 million

CAGR: 10.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $13.3 million

CAGR: 10.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sickle Cell Disease Diagnosis and Treatment Market Overview

The Sickle Cell Disease Diagnosis and Treatment market refers to the industry focused on diagnosing and treating sickle cell disease, a genetic disorder that affects hemoglobin production. As the Sickle Cell Disease Diagnosis and Treatment market size is expected to reach $4.4 billion by 2026, the growth outlook and market forecast indicate a significant expansion of the industry. The primary keywords in this context, including Sickle Cell Disease Diagnosis and Treatment market size, growth outlook, market forecast, and industry expansion, are crucial in understanding the scope of this market, which encompasses various synonyms such as sickle cell anemia diagnosis and treatment, and hemoglobinopathy management.

Loading chart…

The current Sickle Cell Disease Diagnosis and Treatment market is driven by a growth forecast with a compound annual growth rate (CAGR) of 10.3%, and macro drivers such as advancements in genetic testing, increasing awareness about sickle cell disease, and government initiatives to improve healthcare infrastructure. Key forces shaping the industry include technology shifts towards point-of-care diagnostics, regulations supporting the development of novel therapies, and consumer behavior favoring personalized medicine. The largest region in the Sickle Cell Disease Diagnosis and Treatment market is North America, while the fastest-growing region is expected to be the Asia-Pacific. As the industry continues to evolve, it is crucial for stakeholders to stay informed about the latest trends and developments shaping the Sickle Cell Disease Diagnosis and Treatment market.

Report Overview

Report Attribute	Details
Market size value in 2025	13.30 million
Revenue forecast in 2033	30.21 million
Growth rate	CAGR of 10.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Emmaus Medical; Addmedica; Gamida Cell; GlycoMimetics; Pfizer; Novartis; Global Blood Therapeutics; Micelle BioPharma; Bluebird Bio; Prolong Pharmaceuticals; Modus Therapeutics; Sangamo Biosciences; Bioverativ; Imara; Ironwood Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sickle Cell Disease Diagnosis and Treatment market is poised for significant growth, driven by increasing awareness and advancements in diagnostic technologies. The Sickle Cell Disease Diagnosis and Treatment market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in genetic testing and point-of-care diagnostics are improving diagnosis rates and enabling early intervention, driving growth in the Sickle Cell Disease Diagnosis and Treatment market

Government initiatives and funding for research and development of novel therapies are expected to boost the Sickle Cell Disease Diagnosis and Treatment market size and growth forecast

Restraints2 items

High costs associated with genetic testing and specialized treatments are limiting access to care, constraining growth in the Sickle Cell Disease Diagnosis and Treatment market

Limited awareness and understanding of Sickle Cell Disease in certain regions are hindering diagnosis and treatment rates, impacting the Sickle Cell Disease Diagnosis and Treatment market size

Opportunities2 items

Emerging markets in Africa and Asia present significant opportunities for growth, driven by increasing awareness and improving healthcare infrastructure, shaping the Sickle Cell Disease Diagnosis and Treatment market

The development of novel, curative therapies, such as gene editing and gene therapy, is expected to transform the Sickle Cell Disease Diagnosis and Treatment market and drive growth forecast

Challenges2 items

The Sickle Cell Disease Diagnosis and Treatment market faces challenges in ensuring equitable access to care, particularly in low-resource settings, affecting the Sickle Cell Disease Diagnosis and Treatment market size

The need for ongoing research and development to address the complex and multifaceted nature of Sickle Cell Disease requires sustained investment and collaboration, influencing the growth forecast

Market Segmentation

Loading chart…

The Sickle Cell Disease Diagnosis and Treatment market can be segmented based on Application, which includes diagnosis and treatment. Diagnosis is further divided into laboratory tests and imaging tests, while treatment includes medications, blood transfusions, and bone marrow transplants. Understanding the Sickle Cell Disease Diagnosis and Treatment segmentation is crucial for market players to develop targeted strategies and products.

The Types segment of the Sickle Cell Disease Diagnosis and Treatment market consists of subtypes such as HbSS, HbSC, and HbSβ+ thalassemia. Each subtype has distinct characteristics and requires specific diagnosis and treatment approaches. Analyzing these subtypes is essential for determining the overall market size and growth prospects. The market taxonomy of Sickle Cell Disease Diagnosis and Treatment involves examining these subtypes to identify trends and opportunities.

Sickle Cell Disease Diagnosis and Treatment Segmentation Breakdown6 items

Application

Child

Adult

Types

Diagnosis

Treatment

Regional Insights

Loading chart…

The Sickle Cell Disease Diagnosis and Treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be the Asia Pacific, driven by increasing adoption of advanced diagnostic technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, ecosystem maturity, high demographics awareness, and established infrastructure; for Europe, increasing funding for research, growing demand for personalized medicine, and favorable regulatory frameworks; for Asia Pacific, large patient population, rising healthcare expenditure, and expanding healthcare access; for Latin America, improving economic conditions, increasing awareness of sickle cell disease, and growing demand for diagnostic services; and for Middle East & Africa, developing healthcare infrastructure, rising prevalence of sickle cell disease, and increasing government initiatives to improve healthcare services.

The regional forecast indicates that the Sickle Cell Disease Diagnosis and Treatment market will experience significant growth, driven by increasing awareness and adoption of diagnostic and therapeutic technologies. Understanding the regional dynamics and key drivers is crucial for stakeholders to navigate the regional forecast and capitalize on emerging opportunities.

Competitive Landscape

The Sickle Cell Disease Diagnosis and Treatment market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Sickle Cell Disease Diagnosis and Treatment competitive landscape is driven by companies seeking to differentiate themselves through innovative products and services. Key competitive levers include pricing strategies, strong distribution networks, and investments in research and development to improve product portfolios.

Companies in this market are adopting various strategies to stay competitive, including mergers and acquisitions, partnerships, and product launches. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To address these challenges, companies are focusing on strategic initiatives such as regional expansion, innovation pipelines, and local manufacturing.

Emmaus Medical: regional expansion

Addmedica: innovation pipeline

Gamida Cell: premium pricing

GlycoMimetics: local manufacturing

Pfizer: vertical integration

Novartis: OEM tie-ups

Key Sickle Cell Disease Diagnosis and Treatment Companies15 items

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Market Ecosystem

The Sickle Cell Disease Diagnosis and Treatment ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and channels, to downstream end users. Value is created and captured through the development, manufacturing, and distribution of diagnostic equipment, treatments, and services, ultimately reaching patients through various channels. This ecosystem is characterized by a range of interactions and interdependencies, influencing the adoption and effectiveness of diagnosis and treatment solutions.

Raw material/component suppliers — providing critical components

Technology providers — developing diagnostic technologies

OEMs / manufacturers — producing diagnostic equipment and treatments

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering maintenance and support services

Regulators/standards bodies — setting standards and approving treatments

End users / buyers — healthcare providers and patients utilizing diagnosis and treatment solutions

Within the Sickle Cell Disease Diagnosis and Treatment ecosystem, value flows through the development, manufacturing, and delivery of diagnostic and therapeutic solutions. Control points, such as regulatory approvals and reimbursement decisions, significantly influence the adoption of new treatments. Dependency risks, including input constraints and standards compliance, can impact the availability and effectiveness of diagnosis and treatment options. Furthermore, switching costs, partnerships, and interoperability requirements can affect the ability of healthcare providers to adopt new solutions, highlighting the need for a thorough value chain analysis to understand the complex interactions and interdependencies within this ecosystem.

Recent Industry Insights

The Sickle Cell Disease Diagnosis and Treatment industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated the development of novel therapies. Mergers and acquisitions have also played a crucial role in shaping the industry, with companies expanding their portfolios and capabilities. Furthermore, the launch of new products and technologies has improved diagnosis and treatment options for patients. Regulatory changes have also supported the growth of the industry, with authorities approving new treatments and providing funding for research initiatives.

In addition to these developments, there has been a notable shift in consumer and enterprise trends, with a growing focus on personalized medicine and patient-centric care. Funding rounds and expansions have also been prominent, with companies securing investments to support the development of innovative treatments. These advancements are expected to continue driving growth in the Sickle Cell Disease Diagnosis and Treatment market, with the industry poised for significant expansion in the coming years.

Analyst Overview

As the Lead Analyst for this study, my expert view is that the Sickle Cell Disease Diagnosis and Treatment market exhibits a moderate level of attractiveness, driven by growing awareness and increasing investments in research and development. The competitive intensity in this market is relatively high, with several key players vying for market share. Looking ahead, the long-term outlook for the Sickle Cell Disease Diagnosis and Treatment market outlook is promising, with innovations in gene therapy and other treatments expected to drive growth.

The innovation landscape is rapidly evolving, with a focus on personalized medicine and targeted therapies. However, the demand-supply balance remains a concern, with a shortage of effective treatments and a significant unmet need in developing regions. Key risk factors include regulatory challenges, pricing pressures, and the potential for pipeline failures. Despite these challenges, the market is expected to experience steady growth, driven by advances in diagnosis and treatment options.

11 items

1. Executive Summary

2. Sickle Cell Disease Diagnosis and Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sickle Cell Disease Diagnosis and Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sickle Cell Disease Diagnosis and Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Child

6.1.2. Adult

6.2. Global Sickle Cell Disease Diagnosis and Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Diagnosis

6.2.2. Treatment

6.3. Global Sickle Cell Disease Diagnosis and Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sickle Cell Disease Diagnosis and Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sickle Cell Disease Diagnosis and Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sickle Cell Disease Diagnosis and Treatment Market Competition by Key Manufacturers

8.1. Global Sickle Cell Disease Diagnosis and Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sickle Cell Disease Diagnosis and Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Emmaus Medical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Addmedica

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Gamida Cell

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GlycoMimetics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pfizer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Global Blood Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Micelle BioPharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bluebird Bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Prolong Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Modus Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sangamo Biosciences

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Bioverativ

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Imara

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Ironwood Pharmaceuticals

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sickle Cell Disease Diagnosis and Treatment Market

Figure 4: Global Sickle Cell Disease Diagnosis and Treatment Market: Drivers

Figure 5: Global Sickle Cell Disease Diagnosis and Treatment Market: Challenges

Figure 6: Global Sickle Cell Disease Diagnosis and Treatment Market: Trends

Figure 7: Global Sickle Cell Disease Diagnosis and Treatment Market: Opportunity

Figure 8: Global Sickle Cell Disease Diagnosis and Treatment Market: Restraint

Figure 9: Global Sickle Cell Disease Diagnosis and Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sickle Cell Disease Diagnosis and Treatment Market Value (USD Million) By Region

Figure 15: Global Sickle Cell Disease Diagnosis and Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sickle Cell Disease Diagnosis and Treatment Market Value (USD Million) By Region

Figure 23: Global Sickle Cell Disease Diagnosis and Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Sickle Cell Disease Diagnosis and Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sickle Cell Disease Diagnosis and Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sickle Cell Disease Diagnosis and Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sickle Cell Disease Diagnosis and Treatment Market Value (USD Million) By Region

Table 10: Global Sickle Cell Disease Diagnosis and Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Sickle Cell Disease Diagnosis and Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sickle Cell Disease Diagnosis and Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sickle Cell Disease Diagnosis and Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Emmaus Medical Basic Information And Sales Area

Table 31: Emmaus Medical. Products Portfolio

Table 32: Addmedica Basic Information And Sales Area

Table 33: Addmedica. Products Portfolio

Table 34: Gamida Cell Basic Information And Sales Area

Table 35: Gamida Cell. Products Portfolio

Table 36: GlycoMimetics Basic Information And Sales Area

Table 37: GlycoMimetics. Products Portfolio

Table 38: Pfizer Basic Information And Sales Area

Table 39: Pfizer. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Global Blood Therapeutics Basic Information And Sales Area

Table 43: Global Blood Therapeutics. Products Portfolio

Table 44: Micelle BioPharma Basic Information And Sales Area

Table 45: Micelle BioPharma. Products Portfolio

Table 46: Bluebird Bio Basic Information And Sales Area

Table 47: Bluebird Bio. Products Portfolio

Table 48: Prolong Pharmaceuticals Basic Information And Sales Area

Table 49: Prolong Pharmaceuticals. Products Portfolio

Table 50: Modus Therapeutics Basic Information And Sales Area

Table 51: Modus Therapeutics. Products Portfolio

Table 52: Sangamo Biosciences Basic Information And Sales Area

Table 53: Sangamo Biosciences. Products Portfolio

Table 54: Bioverativ Basic Information And Sales Area

Table 55: Bioverativ. Products Portfolio

Table 56: Imara Basic Information And Sales Area

Table 57: Imara. Products Portfolio

Table 58: Ironwood Pharmaceuticals Basic Information And Sales Area

Table 59: Ironwood Pharmaceuticals. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Sickle Cell Disease Diagnosis and Treatment Market Value (USD Million) By Region

Table 65: Global Sickle Cell Disease Diagnosis and Treatment Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Sickle Cell Disease Diagnosis and Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.30 million
Revenue forecast in 2033	30.21 million
Growth rate	CAGR of 10.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Emmaus Medical; Addmedica; Gamida Cell; GlycoMimetics; Pfizer; Novartis; Global Blood Therapeutics; Micelle BioPharma; Bluebird Bio; Prolong Pharmaceuticals; Modus Therapeutics; Sangamo Biosciences; Bioverativ; Imara; Ironwood Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in genetic testing and point-of-care diagnostics are improving diagnosis rates and enabling early intervention, driving growth in the Sickle Cell Disease Diagnosis and Treatment market

Government initiatives and funding for research and development of novel therapies are expected to boost the Sickle Cell Disease Diagnosis and Treatment market size and growth forecast

Restraints2 items

High costs associated with genetic testing and specialized treatments are limiting access to care, constraining growth in the Sickle Cell Disease Diagnosis and Treatment market

Limited awareness and understanding of Sickle Cell Disease in certain regions are hindering diagnosis and treatment rates, impacting the Sickle Cell Disease Diagnosis and Treatment market size

Opportunities2 items

The development of novel, curative therapies, such as gene editing and gene therapy, is expected to transform the Sickle Cell Disease Diagnosis and Treatment market and drive growth forecast

Challenges2 items

Market Segmentation

Loading chart…

Sickle Cell Disease Diagnosis and Treatment Segmentation Breakdown6 items

Application

Child

Adult

Types

Diagnosis

Treatment

Regional Insights

Loading chart…

Competitive Landscape

Emmaus Medical: regional expansion

Addmedica: innovation pipeline

Gamida Cell: premium pricing

GlycoMimetics: local manufacturing

Pfizer: vertical integration

Novartis: OEM tie-ups

Key Sickle Cell Disease Diagnosis and Treatment Companies15 items

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Market Ecosystem

Raw material/component suppliers — providing critical components

Technology providers — developing diagnostic technologies

OEMs / manufacturers — producing diagnostic equipment and treatments

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering maintenance and support services

Regulators/standards bodies — setting standards and approving treatments

End users / buyers — healthcare providers and patients utilizing diagnosis and treatment solutions

Recent Industry Insights

Analyst Overview

Table of Contents